The gene for the MM surface antigen BCMA, selected as a control marker gene for MM, was expressed at a 2.4-fold higher level in malignant plasma cells from MM patients than normal plasma cells (Figure 1, Table S1). Here, TNFRSF17 is linked to Miyoshi myopathy.